Cannaray Restricted, a number one European medical hashish firm headquartered in London, is thrilled to announce it has signed a definitive settlement to merge with Aqualitas Inc., a Nova Scotia-licenced, medical hashish cultivator and processor and drug institution license (DEL) holder with EU GMP, cGMP, GAP & Clear Inexperienced(R) natural certifications. Aqualitas is residence to Canada’s prime grower of the yr and has developed an modern cultivation system utilizing residing soil and aquaponic fertilisation from the nutrient dense waste of three,000 koi carp fish, which has produced award-winning medical hashish merchandise.
This landmark merger marks a pivotal second within the European medical hashish sector, emphasizing the dedication of each Cannaray and Aqualitas to offering prime quality and constant medical hashish merchandise for sufferers in want.
Aqualitas is becoming a member of forces with Cannaray’s extremely regarded medical hashish divisions, Therismos GmbH (Germany) and Therismos Restricted (UK). Therismos companions with key opinion leaders in ache, psychiatry and different indications to offer sufferers with the perfect hashish remedy and dosing tips. In Germany, Therismos has a strong partnership with Walgreens Boots Alliance’s German subsidiary Alliance Healthcare/GEHE which has 4,000 cooperation companion pharmacies within the ‘Alphega’ and ‘gesund leben’ community. Within the UK Therismos has a longtime medical hashish meting out pharmacy and medical hashish clinic.
With the latest hashish legalisation modifications in Germany, this merger positions the mixed entity uniquely available in the market, creating a worldwide, vertically built-in enterprise to deliver constant, high-quality and cost-effective treatment to the affected person.
Final yr the mixed corporations generated gross sales of US$51M. This merger delivers the promise of even better development by vertical integration, an enormous distribution community, and distinctive, high-quality, Clear Inexperienced(R) licensed natural medical hashish merchandise.
M. Scott Maguire, CEO of Cannaray, expresses pleasure for the long run, stating, “We’re delighted to have discovered Aqualitas, an organization that has developed merchandise with the affected person on the forefront and shares our dedication to excellence. We’re positioned to play a number one function in Germany the place the German market is anticipated to develop exponentially because of the approaching declassification of hashish from a narcotic to a non-narcotic. We shall be one of many few European corporations with a seed-to-shelf operation within the UK and Germany.”
Myrna L. Gillis, CEO of Aqualitas, remarks, “This worldwide merger with Cannaray is a big milestone, reflecting our dedication to excellence in manufacturing clear, constant, and secure medical hashish merchandise. Collectively, we share a imaginative and prescient of delivering the most effective treatment in a wide range of codecs to offer physicians and sufferers the most effective therapeutic choices.”
